Century Therapeutics, Inc’s Post

Which #cancers are HCPs talking about online at American Society of Clinical Oncology (ASCO) ? Presentations on studies such as the #CROWN and #PALOMA-3 trials are causing the #lungcancer conversation to dominate. Watch this space for more updates from the next three days of #ASCO24! #WhatHCPsThink

A new read from our team is out in IOVS (Ocular Oncology Special Issue).  Not 100 μl, even 1 μl of aqueous humor has implications for clinical testing of retinoblastoma. More insights can be read at https://lnkd.in/gXpa6MNF

This new study in BMJ Oncology highlights that despite the known crucial importance of health-related quality of life outcomes, their reporting remains suboptimal. https://lnkd.in/eiT-mcDe

When you are completing an oncology study you need to have new approaches and fresh ideas to overcome the vast complications that can appear – and Stiris is your answer. Our team of clinical research veterans know what it takes to bring oncology studies to success, and regardless of the size of the study you will always get our A team. Want to know more about how Stiris can make your Oncology studies successful? Reach out to us (Info@StirisResearch.com) and we would be happy to share! #OutOfTheBox #ClinicalTrials #OncologyTrials #ClinicalResearch #StirisResearch

In this episode of Oncology Today with Dr Neil Love, you can hear the perspectives Dr Petros Grivas shares on research with and ongoing studies evaluating available and investigational agents and strategies for patients with UBC.

🧡Hosted by #SyneosHealth and the Society for Clinical Research Sites (SCRS), our latest on-demand webinar explores the complexities and paths towards enhanced diversity in oncology trials at the site level.   Watch the full webinar here: https://lnkd.in/dXBXVQFd #SyneosHealthLife #WorkHereMattersEverywhere #ClinicalCareers #ClinicalSolutions #DiversityinOncologyTrials

#mesothelioma #cancerresearch ATOMIC-Meso results JAMA Oncology : Phase III study platinum + pemetrexed +/- arginine depleting pegargiminase (ADI-PEG20) for nonepithelioid pleural #mesothelioma (n=249). Adding pegargiminase improved OS (9.3m vs 7.7m, HR 0.71) with 3y OS 11.9% vs 3.3% full article in the comment below ⬇

💡 Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC! This updated analysis showed sustained OS benefit with Single Tremelimumab Regular Interval Durvalumab (STRIDE) vs sorafenib. The study also found that no new serious treatment-related AEs occurred after the primary analysis for STRIDE. Read the full 2024 paper👇 https://ow.ly/nkcw50SSVC4 #MedEd #HCC #LiverCancer Annals of Research in Oncology

Less than two weeks until #ASCO2024. To learn how Translational Drug Development (TD2) can assist in expediting your path to the patient and approval, regardless where you are in the #cancertherapeutic development pathway, stop by Booth 10099! #preclinicaldevelopment #regulatoryconsulting #clinicaltrialmanagement #oncologyfocused #benchtopatient

Here's what you need to know about the current oncology pathway landscape. Read our latest insights: https://lnkd.in/ga2eStH8 #oncologyclinicalpathways #clinicalpathways #marketaccessinsights